Article 49 of the Dutch Medicines Act obliges marketing authorisation holders and manufacturers to report the availability on the market and (possible) shortages of a medicinal product. The Medicine shortages and defects notification centre offers marketing authorisation holders and manufacturers the possibility of submitting various notifications via a central point.

The Medicine shortages and defects notification centre is coordinated by the Medicines Evaluation Board (MEB) and the Health and Youth Care Inspectorate (IGJ).